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Summary
 
Natural killer (NK) cells have been implicated in early immune responses against certain vi-
ruses, including cytomegalovirus (CMV). CMV causes downregulation of class I major histo-
compatibility complex (MHC) expression in infected cells; however, it has been proposed that
a class I MHC homolog encoded by CMV, UL18, may act as a surrogate ligand to prevent NK
cell lysis of CMV-infected cells. In this study, we examined the role of UL18 in NK cell recog-
nition and lysis using fibroblasts infected with either wild-type or UL18 knockout CMV virus,
and by using cell lines transfected with the UL18 gene. In both systems, the expression of
UL18 resulted in the enhanced killing of target cells. We also show that the enhanced killing is
due to both UL18-dependent and -independent mechanisms, and that the killer cell inhibitory
receptors (KIRs) and CD94/NKG2A inhibitory receptors for MHC class I do not play a role
in affecting susceptibility of CMV-infected fibroblasts to NK cell–mediated cytotoxicity.
Key words: cytomegalovirus • class I major histocompatibility complex • UL18 • natural killer 
cell • cytotoxicity
 
H
 
uman cytomegalovirus (hCMV)
 
1
 
 is an extremely
widespread infectious agent. Healthy individuals ac-
quiring hCMV postnatally are usually asymptomatic, al-
though the virus persists in the host for life (1). Both T and
NK cells play a critical role in controlling the initial infec-
tion and the disease that follows viral reactivation in immu-
nocompromised individuals (2, 3). The importance of NK
cells is highlighted by the fact that patients with an NK cell
deficiency are extremely susceptible to hCMV infection
and its associated diseases (4). In addition, NK cells also
play an important role in the control of mouse CMV (5).
Strain-dependent mouse CMV resistance or susceptibility
has been mapped to the NK complex (NKC) region of
murine chromosome 6 (6). The NKC region contains
genes involved in modulating murine NK cell functions
and codes for molecules that can trigger (NKR-P1) or in-
hibit (Ly49) NK cell–mediated cytotoxicity (7). Murine
Ly49 molecules and their human functional counterparts,
the KIRs (killer cell inhibitory receptors) and CD94/
NKG2A receptors, inhibit NK cell cytotoxicity after cog-
nate interaction with class I MHC molecules (8). Since
many viruses downregulate host cell class I MHC expres-
sion upon infection, the hypothesis that NK cell inhibitory
receptors serve as a physiological means to monitor for viral
infection is compelling.
Both human (9) and mouse CMV (10) encode glycopro-
teins with homology to class I MHC heavy chains, desig-
nated UL18 (human) and M144 (mouse), respectively. It
has been suggested that these molecules serve as surrogates
for class I MHC molecules to engage inhibitory NK cell
class I MHC receptors. In support of this hypothesis, Farrel
et al. (10) have shown that mouse CMV lacking the M144
gene is more virulent in vivo
 
.
 
 Transfection studies using
the human CMV UL18 gene have implicated this protein
 
1
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-microglobulin; CHO, Chinese
hamster ovary; cIg, control Ig; hCMV, human cytomegalovirus; HFF,
human foreskin fibroblasts; ICAM-1, intracellular adhesion molecule 1;
KIR, killer cell inhibitory receptor; MOI, multiplicity of infection.
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in the protection of B lymphoblastoid cells from lysis by
NK cells expressing CD94/NKG2A receptor (11). In addi-
tion, Cosman and coworkers (12, 13) have recently dem-
onstrated that UL18 is specifically recognized by LIR-1, a
membrane of the Ig receptor superfamily, which is pre-
dominantly expressed on monocytes, B cells, and a minor
subset of NK cells (12, 13). In this study we examined the
roles of endogenous class I MHC and an hCMV encoded
class I homolog (UL18) in modulating NK cell–mediated
cytotoxicity during hCMV infection.
 
Materials and Methods
 
Cell lines, NK Cell Lines, and Clones.
 
293EBV is a human
kidney cell line expressing the EBNA-1 nuclear antigen (Invitro-
gen, Carlsbad, CA). COS-7, Chinese hamster ovary (CHO)-K1,
293EBV, and human foreskin fibroblast (HFF) cell lines were
maintained in RPMI (MediaTech, Herndon, VA) supplemented
with 10% FCS (GIBCO BRL, Bethesda, MD). NK cells were
cloned and cultured as previously described (14, 15). HFF cell
lines were prepared and cultured as previously described (16).
 
Constructs.
 
The UL18 open reading frame was subcloned
into the EBV episomal expression vectors pREP10 and pCEP4
(Invitrogen). The cDNA for CD32 and CD94 were cloned into
pBJneo. The hCMV gB (UL55) cDNA in the pRcCMV vector
(Invitrogen) was a gift from Dr. L. Pereira (University of Califor-
nia San Francisco, San Francisco, CA).
 
Transient Transfection.
 
293EBV were plated at 60–80% con-
fluence and transfected with pREP10 UL18 using Lipofectamine
(GIBCO BRL). 48 h after transfection, cells were trypsinized and
stained with anti-UL18 mAb (10C7), followed by PE-conjugated
goat anti–mouse IgG. Viable UL18 positive cells were sorted and
cultured for 48 h before use in cytotoxicity assays. COS-7 and
CHO-K1 were transfected with pCEP4 UL18 and sorted as
above. Flow cytometry was performed as previously described (17).
 
Antibodies.
 
10C7 (mouse IgG1) was generated by immuniz-
ing mice with soluble, partially deglycosylated UL18. The mAbs
against KIRs were: DX9 (KIR3DL1); DX27 (KIR2DL2,
KIR2DL3, and KIR2DS2); DX30 (KIR3DL1, KIR3DL2);
DX31 (KIR3DL2); and HP-3E4 (KIR2DL1, KIR2DS1, and
KIR2DS4). DX22 mAb is against CD94. Anti–class I mAbs
(DX15, DX16, and DX17) have been previously described (18).
Anti-CMV UL55 (gB) was purchased from the Goodwin Insti-
tute (Goodwin Institute, Plantation, FL). Anti-hCMV IE mAb
was purchased from Chemicon (Temecula, CA). All other mAbs
were provided by Becton Dickinson Immunocytometry Systems
(San Jose, CA).
 
Cytotoxicity Assays.
 
Cell-mediated cytotoxicity was assessed
using 4-h 
 
51
 
Cr–release assays. In these assays, effector cells at vari-
ous concentrations were incubated with 5 
 
3 
 
10
 
3
 
 target cells in
U-bottomed 96-well microtiter plates at 37
 
8
 
C. Percentage of lysis
was determined as previously described (18). Spontaneous 
 
51
 
Cr
release was 
 
,
 
10% of total counts. Only cells with 
 
.
 
80% viability
were used for labeling. The spontaneous release of 293EBV
UL18 cells and 293EBV controls were similar.
 
Western Blot.
 
Infected HFFs were lysed in 0.5 ml of lysis
buffer (Tris buffered saline, 50 mM Tris, 150 mM NaCl, pH 8.0,
with 1% NP-40). Lysates were resolved by SDS-PAGE on 12%
gels. Western blots were performed using 10C7 anti-UL18 or
anti-hCMV IE mAbs, followed by horseradish peroxidase–conju-
gated second antibodies as previously described (19).
 
hCMV Infection.
 
AD169 and 
 
D
 
18 (20) viruses were titered
and propagated in HFFs as previously described (16). HFFs were
infected at a multiplicity of infection (MOI) of 3–5. After adsorp-
tion of the virus for 1 h at 37
 
8
 
C, the inoculum was removed and
medium containing 10% FCS was added. Viral stocks were ti-
tered using classical cytopathic effect as an end-point.
 
Results and Discussion
 
The Role of Endogenous Class I in Modulating NK Cell Kill-
ing of Infected and Uninfected HFFs.
 
Fibroblasts downregu-
late class I MHC expression upon hCMV infection (21). In
Fig. 1 
 
A
 
, we show that class I MHC is downregulated 10-
fold in hCMV-infected HFFs, but a significant level of class
I MHC is still present on the cell surface. This downregula-
tion was seen by 24 h and was maintained for the duration
of the studies (5 d, data not shown). The ‘missing self’ hy-
pothesis stipulates that the loss of class I MHC expression
confers susceptibility to NK cell killing (22). The expecta-
tion from this hypothesis is that infected cells would be-
come more susceptible to NK cell–mediated lysis. To ad-
dress this question, we performed NK cell cytotoxicity
assays using hCMV-infected and mock-infected cells. In
repeated experiments, NK cells efficiently lysed hCMV-
infected HFFs, but not mock-infected cells (Fig. 1 
 
B
 
). This
inability to efficiently kill mock-infected HFFs may be due
to their high level of class I MHC expression. If NK cells
were restrained from killing uninfected HFFs by a class I
MHC–dependent mechanism, blocking the KIRs and/or
CD94/NKG2A receptors on the effector cells or class I
MHC on the fibroblasts should reverse the protection. Ex-
periments performed with anti–class I or a cocktail of mAbs
against CD94 and KIRs did not induce killing (Fig. 1 
 
C
 
).
This inability to kill was evident using a variety of NK
clones and lines (data not shown). The KIR and CD94/
NKG2A receptors expressed by these NK cells were func-
tional against B lymphoblastoid target cells transfected with
relevant class I MHC genes, with the target cell protection
being reversed using anti–class I MHC or anti-CD94 
 
1
 
anti-KIR mAbs. Therefore, class I MHC expression alone
by HFFs does not prevent NK cell–mediated killing. It can
be argued that mock-infected HFFs lack positive signals
needed to trigger NK cells, and that class I MHC may be
functional in the context of infected cells, which have up-
regulated ligands for the ‘triggering’ receptors. To address
this, we repeated these experiments using hCMV-infected
HFFs. Again, blocking class I MHC, KIRs, or CD94 nei-
ther augmented nor attenuated NK cell–mediated cytotox-
icity (Fig. 1 
 
D
 
).
 
The Role of a Virus-encoded Class I MHC Homolog in NK
Cell Killing.
 
hCMV encodes a glycoprotein with homol-
ogy to class I MHC (9). This molecule is able to form a
complex with 
 
b
 
2
 
-microglobulin (
 
b
 
2
 
M)(23) and contains a
peptide-binding groove (24). KIR recognition of class I
MHC requires the formation of a trimeric complex com-
prising class I MHC, 
 
b
 
2
 
M, and peptide (25, 26). It was
therefore hypothesized that UL18 would interact with NK
cell class I receptors to inhibit killing of CMV-infected 
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cells. We examined this by infecting HFFs with wild-type
AD169 CMV virus or 
 
D
 
18 (a mutant virus with the UL18
gene deleted). The level of class I MHC downregulation
by the two viruses was comparable (Fig. 2 
 
A
 
). A 69-kD
UL18 protein was detectable by 24 h in AD169-infected
HFFs by Western blot analysis, but not in 
 
D
 
18-infected
HFF lysates (Fig. 2 
 
B
 
). Although UL18 protein was readily
detected by Western blot analysis in HFF infected with
AD169 virus, analysis by flow cytometry suggested that
very little UL18 was expressed on the cell surface (data not
shown). The amounts of hCMV IE protein (Fig. 2 
 
B
 
) and
class I MHC (data not shown) in lysates prepared from
 
D
 
18-infected HFFs were comparable to those detected in
HFF infected with AD169 wild-type CMV. Furthermore,
the titer of AD169 and 
 
D
 
18 viruses were comparable, as as-
sessed by plaque formation assays (data not shown) and the
HFFs were homogeneously infected as assessed by the uni-
form downregulation of class I in all the cells (Fig. 2 
 
A
 
).
Many NK cell lines and clones killed AD169-infected cells
somewhat better than they did 
 
D
 
18-infected cells (Fig. 2
 
C
 
). However, HFFs infected with AD169 or 
 
D
 
18 showed
enhanced killing when compared with mock infected cells
(Fig. 2 
 
C
 
). Therefore, UL18 confers a slight enhancement
of susceptibility to NK cell killing, although UL18-inde-
pendent mechanism(s) also exists.
To examine directly the ability of UL18 to confer in-
creased susceptibility to NK cell killing in the absence of
viral infection, we transfected 293EBV cells with a UL18
expression vector. Fig. 2 
 
D
 
 shows the expression of UL18
on the surface of transfectants using a UL18-specific mAb.
In a series of experiments, 293EBV UL18 cells consistently
showed enhanced lysis compared with 293EBV (Fig. 2 
 
E
 
).
In addition, UL18-dependent enhancement of NK cell
killing could also be demonstrated in transfected COS-7
and CHO-K1 cells (data not shown) using several NK
clones and lines. These clones included those expressing
functional KIRs and CD94 (Table 1). Inhibition of NK
cell killing by UL18-expressing target cells was never ob-
served in any of these experiments. The enhanced lysis of
293EBV cells transfected with UL18 was not affected by
mAbs against CD94 or KIR (data not shown), although it
should be noted that not all KIR isoforms are recognized
by the available mAbs. The enhanced killing of 293EBV
UL18 transfectants versus 293EBV was not due to changes
in the level of class I MHC or adhesion molecules (data not
shown). As controls, cells were transfected with expression
constructs encoding CD32, CD94, an hCMV surface gly-
coprotein (gB), or vector only; none of these transfectants
showed enhanced susceptibility to NK cell lysis (data not
shown).
Hence, the hypothesis that UL18 replaces class I MHC
molecules to prevent NK cell lysis does not seem to apply
to hCMV-infected HFFs and transfected epithelial and
ovary cells (293, COS-7, and CHO-K1). It was recently
reported that UL18 inhibits NK cell lysis of 721.221 B
lymphoblastoid targets, mediated through CD94 (11). In
repeated studies, we never observed inhibition of NK cell
Figure 1. (A) Downregulation of class I MHC in hCMV-infected
HFFs. AD169 or mock-infected HFFs were stained with anti–class I
(DX17) or control Ig (cIg), followed by PE-conjugated goat anti–mouse
Ig. HFFs were infected with AD169 at an MOI of 3, and cells were
stained at 24 h after infection. (B) NK cell cytotoxicity assay against
hCMV or mock-infected HFF cells. hCMV or mock-infected HFFs were
used as targets in a 4-h 51Cr–release assay. HFFs were infected at an MOI
of 3 and used at 48 h after infection. Mock-infected, white squares;
AD169,  black diamonds. (C) Blocking class I MHC, KIR, or CD94 does
not induce NK cell killing of uninfected HFFs. Normal HFFs were incu-
bated in the presence of NK cells and with cIg or a mixture of mAb
against class I MHC (DX15, DX16, and DX17 at 20 mg/ml) or a mixture
of anti-KIR mAbs (DX27, DX30, DX31, and HP-3E4) and anti-CD94
mAb (DX22), each at 20 mg/ml. cIg, black bars; anti-KIR/CD94, gray
bars; anti–class I, hatched bars. (D) AD169 or mock-infected HFFs were in-
cubated in the presence of NK cells with cIg or mAb directed at class I
MHC (DX15, DX16, and DX17 at 20 mg/ml) or a cocktail of mAbs
against KIR and CD94. Cytotoxicity assays were performed at E/T ratios
of 5:1. As controls, 721.221 class I HLA transfectants expressing HLA-
B*0702 or HLA-Cw*0702 were analyzed, using NK clones expressing
the relevant CD94/NKG2A or KIR, respectively. cIg, white bars; anti-
KIR/CD94, black bars; anti–class I, hatched bars. 
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killing against UL18 expressing targets using clones with
functional CD94 or KIR. In view of this discrepancy, sev-
eral aspects of the previous report should be highlighted.
First, in the prior study UL18 was transfected into 721.221
targets; however, transfectants were isolated on the basis of
surface 
 
b
 
2
 
M expression, not UL18. Second, we have failed
to generate stable UL18 transfectants in 721.221 or in 15
other human or mouse lines, because it seems that pro-
longed expression (
 
.
 
2 wk) of UL18 results in cell death.
We could only generate UL18 transfectants in high effi-
ciency transient transfection systems such as 293, COS-7,
and CHO-K1. Notably, 721.221 cells express low levels of
HLA-E (27) and -F (28). Since Reyburn et al
 
. 
 
(11) sorted
UL18-transfected 721.221 on the basis of 
 
b
 
2
 
M surface ex-
pression, rather than UL18, cells expressing HLA-E or -F
may have been inadvertently enriched and could be re-
sponsible for the protection against NK cell lysis. In fact, a
Figure 2. (A) Downregulation of class I MHC after D18 and AD169 hCMV infection of HFFs. HFFs were infected with D18 or AD169 at an MOI of
5. At 48 h after infection cells were stained with anti–class I MHC or cIg, followed by PE-conjugated goat anti–mouse second step. (B) Expression of
UL18 in AD169 but not D18 cell lysates. Lysates were prepared from HFF-infected with D18 or AD169 at 48 h after infection and blotted with anti-
UL18 or anti-hCMV IE mAb, followed by horseradish peroxidase–conjugated second step. (C) AD169-infected HFFs were lysed more efficiently than
were D18-infected HFFs. HFFs were infected with AD169 or D18 at an MOI of 5, and used as targets at 48 h after infection in 4-h 51Cr–release assays.
Assays were performed at an E/T ratio of 20:1, 10:1, and 1:1. Standard deviation between triplicates was ,10%. D18, black circles; AD169, black diamonds;
mock-infected, black squares. (D) Surface UL18 expression on 293EBV transfectants. 293EBV cells were transfected with pREP10 UL18. Cells were cul-
tured for 48 h before use in cytotoxicity assays. Histograms of sorted UL18-positive cells. Cells were stained with anti-UL18 mAb 10C7 followed by PE-
conjugated goat anti–mouse Ig. (E) 293EBV transfectant expressing UL18 were lysed at an enhanced level compared with parental controls. UL18-trans-
fected 293EBV cells were used as targets in NK cell cytotoxicity assays. Experiments were performed at an E:T ratio of 5:1. All transfectants other than
vector only were positively sorted using mAb directed against the protein encoded by the transfected cDNA. Cells were cultured for 48 h and used in 4-h
cytotoxicity assays as described above.
 
Table 1.
 
Phenotype of NK Cell Lines and Clones
 
Clones KIRs CD94
A10 DX9
 
2
 
, DX24
 
1
 
CD94
A23 DX9
 
2
 
, DX24
 
1
 
CD94
A26 DX9
 
1
 
, DX24
 
1
 
ND
A25 DX9
 
1
 
, DX24
 
1
 
ND
BR KIR
 
2
 
CD94/NKG2A
B8 KIR
 
2
 
CD94/NKG2A
B11 KIR
 
2
 
CD94/NKG2A
B19 KIR
 
2
 
CD94/NKG2A
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recent study demonstrated that the endogenous HLA-E ex-
pressed by 721.221 cells can protect these target cells from
lysis by NK cells expressing the inhibitory CD94/NKG2A
receptor (29). Although HLA-E molecules bind peptides
derived from the leader segments of certain other MHC
class I proteins (27), the leader of UL18 does not conform
to the preferred peptide bound by HLA-E. Therefore, it is
possible that Reyburn et al. (11) simply selected for a vari-
ant of 721.221 that expressed higher levels of the endoge-
nous HLA-E protein.
Recent studies by Cosman and coworkers (12, 13) have
shown that the human CMV UL18 protein interacts with a
membrane receptor designated ILT2 (30) or LIR-1 (12,
13), which is expressed predominantly on monocytes, B
cells, and a subset of NK cells. Binding of a UL18–Ig Fc fu-
sion protein to NK cells and monocytes was completely
blocked using an anti-ILT2/LIR-1 mAb, suggesting that
ILT2/LIR-1 is the predominant, if not exclusive, receptor
for UL18 expressed on leukocytes (12). It is possible that
ILT2/LIR-1 on NK cells might interact with UL18 on
CMV-infected cells, preventing NK cell–mediated cyto-
toxicity. However, it should be appreciated that ILT2/
LIR-1 is expressed on only a minor subset of NK cells (12,
31); therefore, the physiological significance of ILT2/LIR-1
on NK cells during a CMV infection is uncertain. Al-
though prior studies of UL18 and its mouse homolog
M144 have focused on a potential role for these proteins in
NK cell–mediated immunity (10, 11), an alternative possi-
bility is that these molecules may be more important in af-
fecting monocyte and dendritic cell function during CMV
infection. For example, interactions between UL18 and
ILT2/LIR-1 on monocytes or dendritic cells during a
CMV infection may suppress IL-12 production, which
would in turn limit IFN-g secretion by NK cells and thus
alter the early host immune response. This scenario could
potentially explain the increased virulence of mouse CMV
virus lacking M144 (10). This is of particular interest given
the recent finding that dendritic cells may serve as the res-
ervoir for latent CMV infection (32).
Upregulation of Cell Surface Adhesion Molecules in hCMV-
infected HFFs. Since enhanced killing was observed in
HFF infected with both AD169 and D18, other molecules
in addition to UL18 were also playing a role. To examine
what molecules were upregulated after infection, we
stained mock-infected and hCMV-infected HFFs with a
panel of mAb against cell surface adhesion/costimulatory
molecules. The only molecule examined that was consis-
tently upregulated in the infected cells was intracellular ad-
hesion molecule 1 (ICAM-1; CD54) (Fig. 3 A). Blocking
of ICAM-1 interaction with its ligand using anti–LFA-1b
(CD18) was able to prevent the killing of infected HFF
(Fig. 3 B). These data suggest that ICAM-1 is a crucial
component in NK cell–mediated killing of hCMV-infected
cells, but does not exclude the existence of other molecules
capable of triggering NK cell cytotoxicity.
Based on our observations, the hypothesis that KIRs and
CD94/NKG2A class I MHC inhibitory receptors are a
physiological surveillance mechanism for viral infection
may not be universally applicable. Similarly, we have previ-
ously shown that in certain target cells (e.g., Jurkat and
K562), the expression of an appropriate class I MHC allele
recognized by KIR3DL1 (i.e., HLA-B*5801) was insuffi-
cient to prevent killing of these transfected target cells (14).
hCMV has evolved many strategies that allow its highly
successful dissemination throughout the population. Al-
though infected individuals are generally clinically asymp-
tomatic (1), further viral transmission still occurs. In cases
where the infection is not effectively controlled, death of-
ten results, thereby limiting the opportunity for further vi-
ral dissemination. Therefore, the UL18-dependent and in-
dependent mechanisms may serve to limit the severity of
CMV-induced disease by rendering infected cells more
susceptible to immune destruction.
Figure 3. (A) Upregulation
of ICAM-1 on hCMV-infected
cells. AD169 or mock-infected
HFFs were stained (24 h after in-
fection) with FITC-conjugated
anti–ICAM-1 (LB2 mAb) or
FITC-conjugated cIg. Mean flu-
orescence intensity of ICAM-1
increased from 351 to 705. (B)
Enhanced cytotoxicity against
hCMV-infected HFFs was re-
versed with anti–LFA-1b (CD18).
hCMV or mock-infected HFFs
were incubated with cIg or anti–
LFA-1b (20 mg/ml). 4-h 51Cr–
release assays were performed at
an E/T ratio of 5:1.
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